Education
About Us
Working with TipRanks
Follow Us
ImageneBio (IMA)
NASDAQ:IMA
IMA Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IMA Stock 12 Month Forecast
Average Price Target
$30.00
▲(275.00% Upside)
| Highest Price Target$30.00 | Average Price Target$30.00 | Lowest Price Target$30.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$30
Buy
275.00%
Upside
Initiated
10/24/25
ImageneBio's IMG-007: A Promising Blockbuster in Atopic Dermatitis with Strategic Leadership and Competitive EdgeWe are initiating coverage of Imagene (IMA) with an OP rating and a PT of $30, based on a discounted cash flow (DCF) analysis. IMA’s fully-diluted market cap is ~ $86M (closing price of $7.39 and 11.7M FD shares outstanding, incl. PIPE shares), and we calculate EV of -$52M using estimated net cash of ~$138M as of Sept 30. We view shares as dramatically undervalued, particularly following a selloff in the wake of disappointing competitor SAN FP (OP) amlitelimab results on Sept 4 – see Exhibit 4. IMA was formed through the merger of Inmagene and IKNA (not rated), which closed on July 25, 2025. The company raised $75M, and mgmt anticipates cash runway through 2027. IMA’s lead asset IMG-007, a non-depleting anti-OX40 monoclonal antibody, is a potential blockbuster atopic dermatitis (AD).
William Blair
―
Buy
―
Reiterated
05/08/25
H.C. Wainwright
$4
Buy
-50.00%
Downside
Reiterated
11/11/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$30
Buy
275.00%
Upside
Initiated
10/24/25
ImageneBio's IMG-007: A Promising Blockbuster in Atopic Dermatitis with Strategic Leadership and Competitive EdgeWe are initiating coverage of Imagene (IMA) with an OP rating and a PT of $30, based on a discounted cash flow (DCF) analysis. IMA’s fully-diluted market cap is ~ $86M (closing price of $7.39 and 11.7M FD shares outstanding, incl. PIPE shares), and we calculate EV of -$52M using estimated net cash of ~$138M as of Sept 30. We view shares as dramatically undervalued, particularly following a selloff in the wake of disappointing competitor SAN FP (OP) amlitelimab results on Sept 4 – see Exhibit 4. IMA was formed through the merger of Inmagene and IKNA (not rated), which closed on July 25, 2025. The company raised $75M, and mgmt anticipates cash runway through 2027. IMA’s lead asset IMG-007, a non-depleting anti-OX40 monoclonal antibody, is a potential blockbuster atopic dermatitis (AD).
William Blair
―
Buy
―
Reiterated
05/08/25
H.C. Wainwright
$4
Buy
-50.00%
Downside
Reiterated
11/11/24
Best Analysts Covering ImageneBio
1 Month
xxx
Success Rate
3/8 ratings generated profit
Average Return
+4.15%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 37.50% of your transactions generating a profit, with an average return of +4.15% per trade.
3 Months
xxx
Success Rate
4/8 ratings generated profit
Average Return
-2.64%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -2.64% per trade.
1 Year
Success Rate
1/8 ratings generated profit
Average Return
-28.85%
reiterated a buy rating 12 months ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -28.85% per trade.
2 Years
xxx
Success Rate
0/8 ratings generated profit
Average Return
-63.38%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -63.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IMA Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Mar 25
Apr 25
May 25
Strong Buy
0
0
0
0
0
Buy
3
1
1
1
2
Hold
1
1
2
2
2
Sell
5
5
4
1
1
Strong Sell
0
0
0
0
0
total
9
7
7
4
5
Each month's total comprises the sum of three months' worth of ratings.
IMA Financial Forecast
IMA Stock Forecast FAQ
What is IMA’s average 12-month price target, according to analysts?
Based on analyst ratings, ImageneBio’s 12-month average price target is 30.00.
What is IMA’s upside potential, based on the analysts’ average price target?
ImageneBio has 275.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IMA a Buy, Sell or Hold?
ImageneBio has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is ImageneBio’s price target?
The average price target for ImageneBio is 30.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $30.00. The average price target represents 275.00% Increase from the current price of $8.
The highest analyst price target is $30.00 ,the lowest forecast is $30.00. The average price target represents 275.00% Increase from the current price of $8.
What do analysts say about ImageneBio?
ImageneBio’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of IMA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.